Skip to main content

Recce Pharmaceuticals further strengthens market monopoly for anti-infectives

Recce Pharmaceuticals Ltd (ASX:RCE) CEO James Graham tells Proactive that the company has been given a boost from the Australian Patent Office, which has issued notification of ‘intent to grant’ for the first of Recce’s new Patent Family 4 anti-infectives. The patent covers the 'Process for Preparation of Biologically Active Copolymer' and expires in 2041.

Contact Details

Proactive Investors

Jonathan Jackson

+61 413 713 744

jonathan@proactiveinvestors.com

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.